Condition Directory

Ovarian Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Ovarian Cancer. Browse Ovarian Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 16, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

739

Shown on this page

Current sort

How Ovarian Cancer studies are organized in the registry

Ovarian cancer records are commonly registered as a group — “ovarian, fallopian tube, or primary peritoneal cancer” — so the broader phrasing is normal and not a labeling error. Platinum-sensitivity language (“platinum-resistant,” “platinum-sensitive”) and BRCA status frequently define the study population in titles.

Terms that often appear in related listings

platinum-resistant fallopian tube BRCA PARP

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 433–444 of 739 matching trials for Ovarian Cancer.

Live ClinicalTrials.gov results.

Active filters: "fallopian tube" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Adnexal Masses, Ovarian Cysts, Ovarian Tumors
Interventions: Not listed
Lead sponsor: KU Leuven; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
Interventions: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis, sargramostim; Biological · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: intravenous docetaxel with intraperitoneal oxaliplatin, intravenous oxaliplatin with intraperitoneal docetaxel; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Cabozantinib S-malate, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 410
States / cities: Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 275 more

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Cabozantinib S-malate, Laboratory Biomarker Analysis, Paclitaxel; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 173
States / cities: Mobile, Alabama • Burbank, California • Concord, California + 119 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: Ketorolac; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Adnexal Mass
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: FIGO Stage IIC-IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
Interventions: carboplatin; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Orange, California

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 4
States / cities: Houston, Texas

Conditions: Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer
Interventions: Carboplatin, Olaparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Neoplasms
Interventions: Anetumab ravtansine (BAY94-9343), Pegylated Liposomal Doxorubicin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Aurora, Colorado • New Haven, Connecticut • Oklahoma City, Oklahoma

Conditions: Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Levonorgestrel, Placebo; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 66
States / cities: Duarte, California • Los Angeles, California • Orange, California + 46 more

About this Ovarian Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Ovarian Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ovarian Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Ovarian Cancer clinical trials

How Ovarian Cancer studies are organized in the registry

Filter and sort this condition

Live official records

International Ovarian Tumour Analysis (IOTA) Phase 5

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Natera Ovarian Cancer Detection Assay

Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer

Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

About this Ovarian Cancer clinical trials directory page